SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon informs about press release

15 Dec 2023 Evaluate
Biocon has informed that it enclosed the press release titled ‘Biocon Biologics Recognized as an Asia IP Elite for 2023, IPR Team adjudged as the Team of the Year’. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

419.55 4.30 (1.04%)
30-Jun-2026 14:37 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1872.00
Dr. Reddys Labs. 1365.95
Cipla 1468.00
Zydus Lifesciences 1120.00
Lupin 2437.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: